RCS - Ondine Biomedical - Ondine to present Health Economic Data at ICPIC

Ondine Biomedical

03/09/2025 07:00

RNS Number : 8084X

Ondine Biomedical Inc.

03 September 2025

 

3 September 2025

Ondine to present Health Economic Data at ICPIC 2025

Health Economics Study on Ondine's Steriwave® Selected for Oral Presentation at ICPIC 2025 in Geneva

Ondine Biomedical Inc. (LON: OBI) announces that it was invited to make an oral presentation about health and economic benefits of Steriwave nasal photodisinfection at the 12th International Conference on Prevention & Infection Control (ICPIC) in Geneva, Switzerland. ICPIC is recognized as the leading conference for infection prevention and control, attracting global experts and healthcare innovators. The Company's abstract detailing a health economic analysis by the York Health Economics Consortium (YHEC) has been accepted and upgraded to an oral presentation (session O06). The annual global conference will be held 16-19 September 2025, in Geneva, Switzerland.

This presentation will highlight how Steriwave nasal photodisinfection significantly reduces costs associated with surgical site infections (SSIs), demonstrated in both a patient series of elective hip and knee replacements at Mid Yorkshire Teaching NHS Trust (MYTT) and more extensively in two separate health economic models using literature-derived data across multiple surgical specialties. YHEC's research shows that Steriwave not only improves patient outcomes but also delivers substantial net savings by preventing SSIs in major surgeries.

Simon Sinclair, Chief Medical Officer of Ondine Biomedical said:

"These results are significant for hospital administrators and patients alike, especially with the unprecedented strain on healthcare systems worldwide. Preventing infections is not just about patient safety, it is a critical strategy for conserving resources, improving hospital efficiency, and combating antimicrobial resistance. The Mid Yorkshire data, combined with our rigorous economic modeling, shows how a simple, rapid intervention like Steriwave can have a profound impact on patient outcomes and reduce the economic burden of surgical site infections. This ICPIC recognition underscores Ondine's ongoing commitment to improving hospital infection control with cost-effective healthcare solutions."

Steriwave is a non-invasive and pain-free nasal decolonisation treatment that uses a proprietary light-activated antimicrobial agent to destroy harmful pathogens-including bacteria, viruses, and fungi-in the nose. Steriwave treatment involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light for five minutes. The treatment is effective immediately, takes less than five minutes, and preserves the natural microbiome while offering immediate microbial reduction without the development of resistance. It is widely used in hospitals across Canada and increasingly in the UK.

 

Enquiries:

Ondine Biomedical Inc.
www.ondinebio.com
Carolyn Cross, CEO
+1 604 669 0555
 or via Vane Percy & Roberts
Strand Hanson Limited (Nominated & Financial Adviser)
James Harris, Richard Johnson
+44 (0)20 7409 3494
Peel Hunt LLP (Broker & Joint Financial Advisor)
James Steel, Dr. Chris Golden
+44 (0)20 7418 8900
Vane Percy & Roberts (Media Contact)
Simon Vane Percy
+44 (0)77 1000 5910

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

 
  END

 

 
NRAEXLBBEKLXBBV